PMID- 29277490
OWN - NLM
STAT- MEDLINE
DCOM- 20190122
LR  - 20190122
IS  - 1873-7064 (Electronic)
IS  - 0028-3908 (Linking)
VI  - 145
IP  - Pt A
DP  - 2019 Feb
TI  - Gene-environment interactions informing therapeutic approaches to cognitive and 
      affective disorders.
PG  - 37-48
LID - S0028-3908(17)30636-6 [pii]
LID - 10.1016/j.neuropharm.2017.12.038 [doi]
AB  - Gene-environment interactions drive experience-dependent changes in the brain 
      that alter cognition, emotion and behaviour. Positive engagement with the 
      environment, through novel experience and physical activity, can improve brain 
      function, although the mechanisms mediating such experience-dependent plasticity 
      remain to be fully elucidated. In this article, we discuss the therapeutic value 
      of environmental stimuli, exercise and environmental enrichment (EE), for 
      cognitive and affective disorders, with implications for the understanding and 
      treatment of depression and anxiety disorders. We demonstrate that environmental 
      manipulations are potential therapeutic strategies for improving outcomes in 
      these psychiatric disorders, including beneficial impacts on cognition. We 
      discuss how EE and exercise are therapeutic environmental interventions impacting 
      both affective and cognitive function. Serotonergic (5-HTergic) signaling is 
      strongly implicated in the manifestation of psychiatric disorders and regulates 
      cognitive and emotional processing that can underpin them. Thus, we focus on 
      evidence implicating the serotonergic system in mediating gene-environment 
      interactions to EE and exercise. Finally, we discuss robust gene-environment 
      interactions associated with EE and exercise interventions, and their impacts on 
      specific brain areas, particularly the hippocampus. We focus on potential 
      mediators of this experience-dependent plasticity, including adult neurogenesis 
      and brain-derived neurotrophic factor (BDNF). Furthermore, we explore molecular 
      and cellular mechanisms of experience-dependent plasticity that potentially 
      underlie the restoration of affective and cognitive phenotypes, thus identifying 
      novel therapeutic targets. This article is part of the Special Issue entitled 
      "Neurobiology of Environmental Enrichment".
CI  - Copyright (c) 2017 Elsevier Ltd. All rights reserved.
FAU - Rogers, Jake
AU  - Rogers J
AD  - Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, 
      University of Melbourne, Parkville, Australia.
FAU - Renoir, Thibault
AU  - Renoir T
AD  - Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, 
      University of Melbourne, Parkville, Australia.
FAU - Hannan, Anthony J
AU  - Hannan AJ
AD  - Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, 
      University of Melbourne, Parkville, Australia; Department of Anatomy and 
      Neuroscience, University of Melbourne, Parkville, Australia. Electronic address: 
      anthony.hannan@florey.edu.au.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20171224
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
SB  - IM
MH  - Animals
MH  - Cognition Disorders/*genetics/metabolism/*therapy
MH  - Environment
MH  - Exercise Therapy
MH  - Gene-Environment Interaction
MH  - Humans
MH  - Mood Disorders/*genetics/metabolism/*therapy
OTO - NOTNLM
OT  - Cerebral cortex
OT  - Cognitive disorders
OT  - Cognitive stimulation
OT  - Environmental enrichment
OT  - Exercise
OT  - Experience-dependent plasticity
OT  - Hippocampus
OT  - Mouse models
OT  - Neurological diseases
OT  - Physical activity
OT  - Psychiatric disorders
OT  - Serotonin
EDAT- 2017/12/27 06:00
MHDA- 2019/01/23 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/06 00:00 [received]
PHST- 2017/12/17 00:00 [revised]
PHST- 2017/12/20 00:00 [accepted]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2019/01/23 06:00 [medline]
PHST- 2017/12/27 06:00 [entrez]
AID - S0028-3908(17)30636-6 [pii]
AID - 10.1016/j.neuropharm.2017.12.038 [doi]
PST - ppublish
SO  - Neuropharmacology. 2019 Feb;145(Pt A):37-48. doi: 
      10.1016/j.neuropharm.2017.12.038. Epub 2017 Dec 24.